Selected Publications
Lau-Min KS, Li Yimei, Eads JR, Mamtani R*, Getz KD*: Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma Cancer 9 (128): 1853-1862,2022.
Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R*, Hubbard RA*: Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States J Natl Cancer Inst 4 (114): 571-578,2022.
Marar M, Long Q, Mamtani R, Narayan V, Vapiwala N, Parikh RB: Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone JAMA Netw Open 1 (5): e2142093,2022.
Getz K, Mamtani R, Hubbard RA: Integrating real world data and clinical trial results using survival data reconstruction and marginal moment-balancing weights J Biopharm Stat (10.1080/10543406.2021.1998097): 1-13,2021.
Parikh RB, Min EJ, Wileyto EP, Riaz F, Gross CP, Cohen RB, Hubbard RA, Long Q, Mamtani R: Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial Ineligible Patients with Advanced Solid Cancers. JAMA Onc : 2021.
Frank I Scott, Amneet K Hans, Mark E Gerich, Blair Fennimore, Ronac Mamtani, Ravy K Vajravelu, James D Lewis: Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease Clin Gastroenterol Hepatol 19 (10): 2082-2092.e10,2021.
Brown TJ, Mamtani R, Bange EM: Immunotherapy Adverse Effects JAMA Onc : doi:10.1001,2021.
Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B, Morel J, Szafors P: Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis Arthritis Care Res : doi: 10.1002/acr.24784,2021.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Barrera RM, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani M, Yu EY, Nam K, Imai K, Moreno BH, Alva A, KEYNOTE-361 Investigators: Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Lancet Oncol. 22 (7): 931-945,2021.
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CA, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA*, Mamtani R*, Huang AC*: CD8 + T cells contribute to survival in patients with COVID-19 and hematologic cancer Nat Med 27 (7): 1280-1289.,2021.
Academic Contact Information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia,
PA
19147
Phone: 215-662-7606
Patient appointments: 800-789-7366